Immunotherapy before surgery for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that has not been treated before, confirmed by a biopsy or other tissue test.
- Your doctor believes you are healthy enough for surgery to remove the tumor.
- You are willing and able to follow the study schedule and use birth control if needed.
- Your blood counts and organ function are within certain limits (e.g., adequate white blood cells, hemoglobin, platelets, and kidney/liver function).
- You do not have serious health issues like uncontrolled heart disease, diabetes, or active infections, and have not had other cancers recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
This study tests whether combining two immunotherapy drugs (sintilimab and ipilimumab) with standard procedures to block or destroy the tumor's blood supply can help keep liver cancer from returning after surgery. It is for people whose liver cancer can be removed but has a higher risk of coming back.
This trial tests whether giving two drugs (tislelizumab, an immunotherapy, and lenvatinib, a targeted therapy) before surgery helps patients with small liver cancers in tricky locations. The goal is to shrink the tumor and improve surgical outcomes compared to surgery alone.
This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) plus radiation before surgery works better than radiation alone before surgery for people with resectable liver cancer. It's for those with a single tumor (or a few small nearby spots) that hasn't spread.
This trial tests whether giving immunotherapy (atezolizumab) before liver surgery helps your body fight liver cancer more effectively. It's for people with early-stage liver cancer who are already scheduled for surgery.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
Hear when a new Hepatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.